Literature DB >> 9353046

Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins.

A S Bayer1, M D Ramos, B E Menzies, M R Yeaman, A J Shen, A L Cheung.   

Abstract

Staphylococcal alpha-toxin targets several cell types which are important components of cardiac vegetations in endocarditis, including platelets, erythrocytes, and endothelial cells. We evaluated the in vivo role of Staphylococcus aureus alpha-toxin in experimental endocarditis by using isogenic strains differing in the capacity to produce functional alpha-toxin, including 8325-4 (wild-type strain), DU-1090 (a mutant strain with allelic replacement of the alpha-toxin gene [hla]), DU1090(pH35L) (a mutant strain producing a target cell-binding but nonlytic toxin), DU1090(pDU1212) (a variant of DU1090 carrying the cloned hla gene on a multicopy plasmid), and DU1090(pCL84::hla) (a variant of DU1090 with a single copy of the hla gene cloned into the chromosomal lipase locus). In vitro, wild-type alpha-toxin (from parental strain 8325-4) extensively lysed both erythrocytes and platelets. In contrast, mutant alpha-toxin [from strain DU1090(pH35L)] lysed neither cell type. Following exposure to the wild-type alpha-toxin, platelet lysates were found to contain microbicidal activity against Bacillus subtilis (but not against Micrococcus luteus), as well as against the parental and alpha-toxin variant S. aureus strains noted above. Furthermore, lysate microbicidal activity was heat stable, neutralized by polyanionic filters or compounds, and recoverable from anionic filter membranes by hypertonic saline elution. These characteristics are consistent with those of cationic platelet microbicidal proteins (PMPs). Reverse-phase high-pressure liquid chromatography and polyacrylamide gel electrophoresis confirmed the presence of three distinct PMPs (1, 2, and 3) in platelet lysates. In experimental endocarditis, the two variant staphylococcal strains producing either minimal alpha-toxin or nonlytic alpha-toxin in vitro [strains DU1090 and DU1090(pH35L), respectively] exhibited significantly lower virulence in vivo than the parental strain (decreased intravegetation staphylococcal densities). Paradoxically, the two variant staphylococcal strains producing alpha-toxin at supraparental levels in vitro [strains DU1090(p1212) and DU1090(pCL84::hla)] also exhibited significantly decreased induction rates and intravegetation staphylococcal densities in experimental endocarditis versus the parental strain. The reduced in vivo virulence of the latter variant staphylococcal strains could not be explained by differences in bacteremic clearance or initial adherence to sterile vegetations (compared to the parental strain). These findings suggest that the reduced virulence exhibited by the variant staphylococcal strains in this model was related to pathogenetic events subsequent to bacterial adherence to the damaged endocardium. Excess intravegetation secretion of alpha-toxin, leading to increased PMP release (secondary to either increased platelet secretion or lysis), may well explain the reduced virulence observed in experimental endocarditis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353046      PMCID: PMC175667          DOI: 10.1128/iai.65.11.4652-4660.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Purification of staphylococcal alpha-toxin by adsorption chromatography on glass.

Authors:  P Cassidy; S Harshman
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Effects of interleukin-1, lipopolysaccharide, and streptococci on procoagulant activity of cultured human cardiac valve endothelial and stromal cells.

Authors:  T A Drake; M Pang
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

3.  Experimental bacterial endocarditis. I. Colonization of a sterile vegetation.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

4.  Assay of hemolytic toxins.

Authors:  A W Bernheimer
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

5.  Cytotoxic effects of ingested Staphylococcus aureus on bovine endothelial cells: role of S. aureus alpha-hemolysin.

Authors:  J M Vann; R A Proctor
Journal:  Microb Pathog       Date:  1988-06       Impact factor: 3.738

6.  Staphylococcus aureus induces tissue factor expression in cultured human cardiac valve endothelium.

Authors:  T A Drake; M Pang
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

7.  Cloning and sequencing of sarA of Staphylococcus aureus, a gene required for the expression of agr.

Authors:  A L Cheung; S J Projan
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

8.  Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin.

Authors:  W M Scheld; J A Valone; M A Sande
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

9.  Platelet aggregation by Streptococcus pyogenes.

Authors:  G E Kurpiewski; L J Forrester; B J Campbell; J T Barrett
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets.

Authors:  S Bhakdi; M Muhly; U Mannhardt; F Hugo; K Klapettek; C Mueller-Eckhardt; L Roka
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  58 in total

1.  Staphylococcus aureus, Platelets, and the Heart.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Alpha-toxin is required for biofilm formation by Staphylococcus aureus.

Authors:  Nicky C Caiazza; G A O'Toole
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

Review 3.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

4.  Enhancement of the pathogenicity of Staphylococcus aureus strain Newman by a small noncoding RNA SprX1.

Authors:  Manikandan Kathirvel; Hasmatbanu Buchad; Mrinalini Nair
Journal:  Med Microbiol Immunol       Date:  2016-07-20       Impact factor: 3.402

Review 5.  Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis.

Authors:  Damon P Eisen
Journal:  Intensive Care Med       Date:  2012-04-25       Impact factor: 17.440

6.  Interleukin (IL)-1β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.

Authors:  Cecilia F Volk; Sarah Burgdorf; Graham Edwardson; Victor Nizet; George Sakoulas; Warren E Rose
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

7.  Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Authors:  Pamela A Moise; Maria Amodio-Groton; Mohamad Rashid; Kenneth C Lamp; Holly L Hoffman-Roberts; George Sakoulas; Min J Yoon; Suzanne Schweitzer; Anjay Rastogi
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Selective activation of sar promoters with the use of green fluorescent protein transcriptional fusions as the detection system in the rabbit endocarditis model.

Authors:  A L Cheung; C C Nast; A S Bayer
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

Review 9.  Salicylic acid: an old dog, new tricks, and staphylococcal disease.

Authors:  Mathias Herrmann
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus.

Authors:  Leon Iri Kupferwasser; Michael R Yeaman; Cynthia C Nast; Deborah Kupferwasser; Yan-Qiong Xiong; Marco Palma; Ambrose L Cheung; Arnold S Bayer
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.